Results 161 to 170 of about 8,797 (225)

Phenotypic and genotypic characterization of single circulating tumor cells in the follow‐up of high‐grade serous ovarian cancer

Molecular Oncology, Volume 20, Issue 6, Page 1535-1555, June 2026.
Single circulating tumor cells (sCTCs) from high‐grade serous ovarian cancer patients were enriched, imaged, and genomically profiled using WGA and NGS at different time points during treatment. sCTCs revealed enrichment of alterations in Chromosomes 2, 7, and 12 as well as persistent or emerging oncogenic CNAs, supporting sCTC identity.
Carolin Salmon, Rui P. L. Neves, Nikolas H. Stoecklein, Sven‐Thorsten Liffers, Jens Siveke, Jan D. Kuhlmann, Pauline Wimberger, Paul Buderath, Rainer Kimmig, Sabine Kasimir‐Bauer   +9 more
wiley   +1 more source

Smartwatches and Smart Scales With Body Composition May Interfere With Cardiac Implantable Electronic Devices. [PDF]

Circ Arrhythm Electrophysiol
Hansen N, Sheppard T, McCoy J, Freedman RA, Bayés-Genís A, Steinberg BA, Sanchez B.   +6 more
europepmc   +1 more source

Six principles for evaluating cognitive capabilities in AI models

AI Magazine, Volume 47, Issue 2, Summer 2026.
Abstract Modern AI systems have exceeded human performance on many benchmarks meant to evaluate general cognitive capacities. However, it is often the case that benchmark performance does a poor job of predicting general capacities in real‐world settings.
Melanie Mitchell
wiley   +1 more source

A Case Report of Non-Neutralizing Acquired Factor V Inhibitor Mimicking Deficiency: Diagnostic Challenges and Therapeutic Implications. [PDF]

Case Rep Hematol
Kalantri S, Pachika P, Balasubramanian S, Alquran B, McCoy M, Sharma V.   +5 more
europepmc   +1 more source

Nanobody‐Conjugated Theranostic Prodrug Targeting αvβ3 Integrin Enables Precision Cancer Therapy With Real‐Time Imaging

Advanced Healthcare Materials, Volume 15, Issue 22, 12 June 2026.
The image shows a schematic form a nanobody‐conjugated theranostic prodrug (NBD) platform targeting tumor‐associated αvβ3 integrin. The NBD system integrates selective nanobody‐mediated tumor recognition, glutathione‐responsive disulfide cleavage for doxorubicin release, and aza‐BODIPY‐based near‐infrared fluorescence for real‐time imaging.
Sanu Karan, Hyunseung Lee, Rema Naskar, Mi Young Cho, Hye Sun Park, Eun Hee Han, Soumyadip Hore, Sun Hee Cho, Truc Ngoc Kim Lam, Taewoong Son, Tae Jung Park, Inkyu Hwang, Jonathan L. Sessler, Kwan Soo Hong   +13 more
wiley   +1 more source

Isolation and characterization of a Chlamydia muridarum tc0237 mutant from a genetic screen that is attenuated in epithelial cells. [PDF]

PLoS One
Jacobs KR, Ardizzone CM, Banerjee A, Toh E, Zhang X, Nelson DE.   +5 more
europepmc   +1 more source

Improved Systemic Immunochemotherapy Employing an Oxaliplatin‐TLR7/8 Agonist Prodrug Strategy

Advanced Science, Volume 13, Issue 31, 4 June 2026.
A platinum(IV) prodrug is developed to systemically deliver the TLR7/8 agonist gardiquimod. Tumor‐targeting is mediated by an albumin‐binding maleimide, which limits premature complex activation. Ox‐Gardi‐Mal accumulates specifically in the tumor, where it activates the immune system.
Michael Gutmann, Martijn Dijkstra, Philipp Salomon, Jamie Cowles, Anja Federa, Dina Baier, Carola Jaunecker, Iemima Semerean, Venla Karvonen, Christine Pirker, Maria Sibilia, Dietmar Herndler‐Brandstetter, Petra Heffeter, Bernhard K. Keppler, Christian R. Kowol, Walter Berger   +15 more
wiley   +1 more source

IFNγ and TNFα optimize salivary gland mesenchymal stromal cells: an alternative to marrow- and adipose-MSCs for radiation xerostomia. [PDF]

Regen Ther
Larsen MC, Gurevic I, Berube L, Vande Loo A, Hanson E, Adam R, Manfrè V, Parker M, Paz C, Galipeau J, Kimple RJ, Blitzer G, McCoy SS.   +12 more
europepmc   +1 more source

Reduced Maintenance DNA Methylation Thresholds Enable Sensitive Reporter Assays for UHRF1 and DNMT1 Inhibition

Advanced Science, Volume 13, Issue 32, 9 June 2026.
The authors engineer colorectal cancer cells with reduced redundancy of UHRF1 and DNMT1, key DNA methylation maintenance factors, lowering the maintenance threshold and sensitizing cells to inhibition. They develop reporter assays driven by endogenous tumor‐suppressor gene promoters with enhanced sensitivity and dynamic range to demethylating drugs ...
Cuicui Xia, Ying Cui, Jiongliang Wang, Wenjing Bai, Danyang Wang, Yao Chen, Huahui Guo, Liangyi Zong, Bing Qin, Xintong Cai, Jie Wang, Jing Huang, Scott B. Rothbart, Zufeng Guo, Stephen B. Baylin, Xiangqian Kong   +15 more
wiley   +1 more source

Development of <i>in vitro</i> potency assays for AAV-based gene silencing therapies targeting FSHD and CMT1A. [PDF]

Mol Ther Adv
McCoy J, Wallace LM, Zhou B, Price B, Salzman R, Harper SQ.   +5 more
europepmc   +1 more source